Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | IKT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.6M | 220.5M |
| IPO Year | 2017 | 2020 |
| Metric | SPCE | IKT |
|---|---|---|
| Price | $3.05 | $2.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.06 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 4.8M | 360.8K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,270.73 | N/A |
| Revenue Next Year | $880.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $1.33 |
| 52 Week High | $8.90 | $2.61 |
| Indicator | SPCE | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 46.52 |
| Support Level | $2.84 | $2.29 |
| Resistance Level | $3.29 | $2.56 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 56.00 | 20.28 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.